- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02222376
Effect of Topic Pirfenidone in Diabetic Ulcers (PirDFI)
Effect of Treatment of Diabetic Foot Ulcers With Topic 8% 1-phenyl-5-methyl-2-[1h]-Pyridone (Pirfenidone) Combined With Modified Disulfur Diallyl Oxide (Odd-m) in Gel.
Pirfenidone is a synthetic molecule, which acts as a potent modulator of the effect of various cytokines (TNF-α, transforming growth factor-β, platelet derived growth factor and vascular endothelial growth factor, among others) that possesses anti-inflammatory and anti-fibrinolytic properties.
The aim of this study is to compare the effect of topic treatment with pirfenidone compared to conventional treatment in chronic diabetic foot ulcers.
The hypothesis is that treatment with topic pirfenidone in chronic diabetic foot ulcers (Wagner 1 to 2) reduces the ulcer size and shortens the healing time compared to conventional treatment. This is a randomized, controlled and crossover study. Patients will be randomly assigned to conventional treatment or topic pirfenidone for eight weeks. At the end of this period they will change groups. Each week ulcers will be for size, depth, length and evidence of infection. The ulcers will have proper debridement in the conventional treatment group and debridement plus topical pirfenidone application in the pirfenidone group. Subjects will be instructed to do daily ulcer cleansing and for those in the topical pirfenidone group, in addition to cleansing they will be instructed to apply the gel twice a day.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Distrito Federal
-
Mexico City, Distrito Federal, Mexico, 14000
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men or women
- Type 1 or 2 diabetes
- Age ≥ 18 years
- Wagner 1 or 2 diabetic foot ulcer
- Diabetic ulcer for more than 8 weeks duration
- Willing to participate in the study with signed informed consent
Exclusion Criteria:
- Ankle/brachial index < 0.4 (critic ischemia)
- Use topical or systemic antibiotics
- Inability to attend to the weekly evaluations
- Inability to do daily ulcer cleansing
- Autoimmune diseases
- Active pharmacologic topical or systemic ulcer treatment
- Treatment with immunosuppressors such as steroids, radiotherapy, chemotherapy
- Pregnancy or lactation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Conventional treatment
Weekly ulcer debridement and daily cleansing
|
Weekly ulcer debridement
|
Experimental: Pirfenidone
Weekly ulcer debridement, daily cleansing, plus twice a day topical pirfenidone application
|
Weekly ulcer debridement
Twice a day topical application
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Ulcer size
Time Frame: 16 weeks
|
16 weeks
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Healed ulcers
Time Frame: 16 weeks
|
16 weeks
|
Adverse effects
Time Frame: 16 weeks
|
16 weeks
|
Healing time
Time Frame: 16 weeks
|
16 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Francisco J Gomez-Perez, MD, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Endocrine System Diseases
- Diabetic Angiopathies
- Leg Ulcer
- Skin Ulcer
- Diabetes Complications
- Diabetes Mellitus
- Diabetic Neuropathies
- Foot Diseases
- Diabetic Foot
- Foot Ulcer
- Ulcer
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Pirfenidone
Other Study ID Numbers
- DIA-1031-13/14-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcers
-
CytomedixCTI Clinical Trial and Consulting ServicesTerminatedDiabetic Foot Ulcers | Wounds | Pressure Ulcers | Leg UlcersUnited States
-
Smith & Nephew, Inc.CompletedDiabetic Foot Ulcers | Venous Leg UlcersUnited States, Canada
-
Arteriocyte, Inc.TerminatedDiabetic Foot Ulcers | Pressure Ulcers | Venous UlcersUnited States
-
Integra LifeSciences CorporationMayo Clinic; Temple University; Samuel Merritt University; New York College of... and other collaboratorsCompletedFoot Ulcers, DiabeticUnited States
-
HealthpointCompletedDiabetic Foot Ulcers | Pressure UlcersUnited States
-
HealthpointCompletedDiabetic Foot Ulcers (DFU) | Venous Stasis Ulcers (VSU)United States
-
Oneness Biotech Co., Ltd.Completed
-
Hadassah Medical OrganizationUnknown
-
Systagenix Wound ManagementUnknownDiabetic Foot UlcersItaly, United States, United Kingdom, Germany, Spain
-
Southern California Institute for Research and...Heritage Medical Research InstituteUnknownDiabetic Foot UlcersUnited States
Clinical Trials on Debridement
-
Smith & Nephew, Inc.TerminatedTorn MeniscusUnited States
-
Medaxis, LLCNAMSARecruitingDiabetic Foot Ulcer | Venous Leg Ulcer | Surgical Wound Dehiscence | Traumatic WoundsUnited States
-
Hospital for Special Surgery, New YorkTerminated
-
North Florida Foundation for Research and EducationNorth Florida/South Georgia Veterans Health System; BiomondeCompletedBacterial Infection | Lower Extremity or Diabetic Foot UlcersUnited States
-
National Taiwan University HospitalUnknown
-
University of MichiganMorita J USACompleted
-
Scil Technology GmbHFGK Clinical Research GmbHUnknownPeriodontal Bone Loss | Alveolar Bone LossHungary
-
Ain Shams UniversityNot yet recruitingPeriodontal Diseases
-
St. Paul's Hospital, CanadaUnknown
-
Southwest Regional Wound Care CenterWithdrawn